Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
CAMBRIDGE, Mass., Feb. 27, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call and webcast at 8:30 a.m. ET on Thursday, March 9, 2017, to discuss its fourth quarter and full-year 2016 financial results and other business highlights.
To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 79789689. The webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.epizyme.com.
March Investor Conferences
In addition, the company will be participating in the following March conferences:
- Cowen and Company 37th Annual Health Care Conference (fireside chat format) on Monday, March 6, 2017 at 4:40 p.m. ET in New York City; and,
- Oppenheimer 27th Annual Healthcare Conference (fireside chat format) on Tuesday, March 21, 2017 at 9:10 a.m. ET in New York City.
Replays of the webcasts of the presentations can be accessed at the investor section of the Company’s website at http://www.epizyme.com.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting cancer treatment through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies as a monotherapy and combination therapy and in relapsed and front-line disease. Using the Company’s proprietary platform, Epizyme has pioneered the identification and development of small molecule inhibitors of chromatin modifying proteins (CMPs), such as tazemetostat. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, which can allow cancer cells to grow and proliferate. By focusing on the genetic drivers of cancers, Epizyme's science seeks to match targeted medicines with the specific patients that need it. For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.
Contacts: Investors Monique Allaire, THRUST IR [email protected] (617) 895-9511 Media Paul Kidwell [email protected] (617) 680-1088
